Edition:
United States

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

9.24USD
4:00pm EDT
Change (% chg)

$0.42 (+4.76%)
Prev Close
$8.82
Open
$8.85
Day's High
$9.31
Day's Low
$8.84
Volume
427,697
Avg. Vol
598,636
52-wk High
$13.41
52-wk Low
$4.81

Chart for

About

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor... (more)

Overall

Beta: 1.96
Market Cap(Mil.): $1,314.37
Shares Outstanding(Mil.): 149.02
Dividend: --
Yield (%): --

Financials

  IMGN.OQ Industry Sector
P/E (TTM): -- 107.68 32.65
EPS (TTM): -1.32 -- --
ROI: -69.50 1.61 12.72
ROE: -- 0.32 14.84

BRIEF-Immunogen Announces Positive Findings From Forward 2 Study Of Mirvetuximab Soravtansine Combination Regimens

* IMMUNOGEN ANNOUNCES POSITIVE FINDINGS FROM THE FORWARD II STUDY OF MIRVETUXIMAB SORAVTANSINE COMBINATION REGIMENS WITH AVASTIN® AND CARBOPLATIN IN OVARIAN CANCER

May 16 2018

BRIEF-ImmunoGen Reports Q1 Loss Per Share $0.30

* IMMUNOGEN REPORTS RECENT PROGRESS AND FIRST QUARTER 2018 OPERATING RESULTS

May 04 2018

BRIEF-Immunogen Completes Interim Analysis For Forward I Phase 3 Trial Of Mirvetuximab Soravtansine

* IMMUNOGEN ANNOUNCES SUCCESSFUL COMPLETION OF INTERIM ANALYSIS FOR FORWARD I PHASE 3 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN PLATINUM-RESISTANT OVARIAN CANCER

Apr 26 2018

Competitors

Earnings vs. Estimates